
## ETCTN Trials by Disease/Treatment Area: Neuroendocrine/Endocrine



## ETCTN Neuroendocrine/Endocrine Cancer Trials (Open as of 7/22/2025

Protocol Number	Phase	Protocol Title
10487	II	A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation
10558	II	A phase II randomized control trial of triapine plus lutetium 177 dotatate versus lutetum 177 dotatate alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors
10479	I	A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors